

Press release - 2012 revenues

Bezons, January 23rd, 2013; 5:45 pm

€27.4 million in revenues for 2012, in line with objectives

Bezons, January 23rd, 2013 – 5:45 pm – RIBER, the global leader for molecular beam epitaxy (MBE), is reporting €27.4 million in revenues for 2012, driven by system sales to research laboratories. Revenues for the fourth quarter of 2012 came to €10.7 million, compared with €10.5 million for the fourth quarter of 2011.

At December 31 st (€'000,000)	2012	2011	Change	2010
Systems	19.4	11.5	+68%	11.1
Services and accessories	5.9	5.4	+9%	6.5
Cells and sources	2.1	12.0	-83%	3.1
Total reported revenues	27.4	29.0	-5%	20.7
Systems order book	10.1	17.4	-42%	13.3
Services and accessories order book	1.7	1.4	+21%	1.8
Cells and sources order book	0.2	0.6	-59%	2.2
Total order book	12.1	19.4	-38%	17.3

In 2012, the decline in sales of cells and sources is offset by the growth in MBE activity. Over the full year, 17 MBE machines were invoiced and delivered, compared with 10 in 2011. With 15 systems in 2012, deliveries to research laboratories climbed to an all-time high.

Sales of services and accessories, supported by a commercial recovery plan launched at the end of 2011, are up 9%, confirming the upturn in business during the second half of the year despite a difficult economic climate.

Sales of evaporation sources and cells are declining due to low investments for OLED production.

At December 31st, 2012, the breakdown of RIBER's revenues was as follows: 42% for Europe (including Russia), 42% for Asia and 16% for the American Continent.

Outlook

During the last quarter of 2012, RIBER recorded orders for three systems for research laboratories in the US and Austria.

At December 31st, 2012, the order book represented €12.1 million (€19.4 million one year earlier). It includes 11 MBE research systems to be delivered in 2013.

The services and accessories business has continued to see a positive trend, with its order book coming in 21% higher than the previous year.

2012 full-year earnings will be released on April 4th, 2013 (before start of trading).

About RIBER:

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, from new information technologies to OLED flat screens and new generation solar cells.

ISO 9001 certified company, Riber recorded €27.4 million in revenues in 2012 and employs 111 people. Riber is listed on NYSE-Euronext Paris (Compartment "C") and is part of the CAC Small, CAC Mid & Small, CAC Technology and CAC T. HARD. & EQ indices.

Riber is one of the best-rated companies in the Gaïa-index, the leading SRI index for French mid-caps.

RIB LISTED NYSE ISIN: FR0000075954 - RIB

Reuters: RIBE.PA Bloomberg: RIB: FP

EURONEXT OSEO-approved innovative company

RIBER

Olivier Handschumacher tel: +33 1 39 96 65 00 invest@riber.com **CALYPTUS**

Cyril Combe tel: +33 1 53 65 68 68

cyril.combe@calyptus.net

www.riber.com